Adverse effects of rofecoxib (continued).
Pharmacovigilance data on rofecoxib, collected after one year on the United Kingdom market, show that it differs little from other NSAIDs. There is a persistent doubt, however, regarding a particular cardiac risk.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D017277:Drug Approval; D005602:France; D006801:Humans; D007783:Lactones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones